ReviewViruses2023
Impact of COVID-19 on Cardiovascular Disease.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials.Saudi medical journal · 2024Pooled it
- Cardiovascular Disease as a Risk Amplifier of COVID-19 Severity and a Potential Correlations to Long-Term Gastrointestinal Sequelae.Journal of racial and ethnic health disparities · 2026Article
- Prognostic impact of right ventricular dilatation and echocardiography use criteria in hospitalized COVID-19 patients.World journal of methodology · 2026Article
- SARS-CoV-2 Vaccination Status and Post-Infection Cardiopulmonary Exercise Performance in Elite Male Team-Sport Athletes.Journal of functional morphology and kinesiology · 2026Article
- COVID-19 advanced cardiovascular and clinical phenotyping dataset.Data in brief · 2026Article
- Cost effective industrial scale synthesis of bromo-benzo[b]azepinone: an intermediate for benazepril.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Distinct Patterns of Clinical Features and Cardiac Biomarker Elevation in Community-Acquired Pneumonia and COVID-19 Pneumonia.Pathogens (Basel, Switzerland) · 2026Article
- The Bacterial, Viral, and Microbiome Contributions in Cardiovascular Diseases: A Narrative Review.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Review
- Significance and Usefulness of High-Resolution 24-h Electrocardiographic Parameters in Patients With Coronavirus Disease 2019 After Admission: A Prospective Cohort Study.Journal of arrhythmia · 2026Article
- COVID-19 and cardiovascular outcomes in patients with pre-existing hypertension.Journal of human hypertension · 2026Review
- Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care.Critical care (London, England) · 2026Article
- Relationship between acute coronary syndrome and coronavirus disease 2019 infection and vaccination type: a retrospective observational study.BMC infectious diseases · 2026Observational
- Trends in cardiovascular disease mortality among older adults with co-occuring lung cancer in the United States from 1999 to 2020.BMC cancer · 2026Article
- Increase in cardiovascular deaths during the COVID-19 pandemic in Peru: a 5-year analysis of the national death system.Open heart · 2026Observational
- Risk factors for death by COVID-19, public hospital in Ciudad Juárez, México.Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Coronary artery calcification is associated with reduced survival in mechanically ventilated COVID-19 patients in the MaastrICCht cohort.Scientific reports · 2026Article
- Effect of COVID-19 vaccination and SARS-CoV-2 infection status on mortality risk in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.Respiratory research · 2026Article
- Self-care and fatigue in individuals hospitalized with decompensated heart failure during the covid-19 pandemic: a cross-sectional study.Revista latino-americana de enfermagem · 2026Observational
- Evaluation of glucose metabolism, endocrine, and renal functions following vaccination in post-COVID-19 individuals: a longitudinal retrospective single-center cohort study.BMC infectious diseases · 2025Article
- Covid-19 and cardiovascular disease in a total population-study of long-term effects, social factors and Covid-19-vaccination.Nature communications · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a viral infection with the novel severe acute respiratory distress syndrome corona virus 2 (SARS-CoV-2). Until now, more than 670 million people have suffered from COVID-19 worldwide, and roughly 7 million death cases were attributed to COVID-19. Recent evidence suggests an interplay between COVID-19 and cardiovascular disease (CVD). COVID-19 may serve as a yet underappreciated CVD risk modifier, including risk factors such as diabetes mellitus or arterial hypertension. In addition, recent data suggest that previous COVID-19 may increase the risk for many entities of CVD to an extent similarly observed for traditional cardiovascular (CV) risk factors. Furthermore, increased CVD incidence and worse clinical outcomes in individuals with preexisting CVD have been observed for myocarditis, acute coronary syndrome, heart failure (HF), thromboembolic complications, and arrhythmias. Direct and indirect mechanisms have been proposed by which COVID-19 may impact CVD and CV risk, including viral entry into CV tissue or by the induction of a massive systemic inflammatory response. In the current review, we provide an overview of the literature reporting an interaction between COVID-19 and CVD, review potential mechanisms underlying this interaction, and discuss preventive and treatment strategies and their interference with CVD that were evaluated since the onset of the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.